Neoadjuvant Immunotherapy Safe for Rectal Cancer Surgery

Neoadjuvant immunotherapy for rectal cancer does not worsen surgical outcomes. A retrospective study of 26,229 patients showed no significant differences in length of stay, readmission, or mortality between those who received immunotherapy and those who did not. This suggests that adding immunotherapy to standard treatment protocols does not increase postoperative complications, offering clinicians valuable insights for optimizing patient-specific treatment strategies.